BioAtla (BCAB) Total Debt (2020 - 2021)
BioAtla (BCAB) posted quarterly Total Debt of $682000.0 for Q2 2021, little changed quarter-over-quarter from $682000.0 in Q1 2021.
BioAtla (BCAB) Total Debt (2020 - 2021) Analysis & Trends
BioAtla's Total Debt history runs 2 years deep, the most recent figure standing at $682000.0 for Q2 2021.
- In Q2 2021, Total Debt changed N/A year-over-year to $682000.0; the TTM figure through Jun 2021 stood at $682000.0 (changed N/A YoY), while the FY2020 annual figure was $682000.0, changed N/A from the prior year.
- Total Debt for Q2 2021 stood at $682000.0, roughly flat from $682000.0 in the prior quarter.
- The five-year high for Total Debt was $682000.0 in Q4 2020, with the low at $682000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.34 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 770.36 Mn |
| 10 | BioAtla | 5.28 Mn | 5.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 682,000.00 |
| Mar 31, 2021 | 682,000.00 |
| Dec 31, 2020 | 682,000.00 |